ACRO Survey Shows Strong Growth of CRO Industry
Members of the Association of Clinical Research Organizations have more than doubled in size in the past 10 years
Members of the Association of Clinical Research Organizations (ACRO) have more than doubled in size in the past 10 years and now employ more than 100,000 research professionals worldwide with a global payroll of nearly $6 billion. Over the same period, member company revenues have increased 180% (10.8% CAGR) to an estimated $14.2 billion, or approximately two-thirds of contract biopharmaceutical development spending, demonstrating the strong demand for CRO services by pharmaceutical, biotech and medical device companies.
Other key findings from the member survey include:
- Among the most researched indications by CROs are, breast cancer, Alzheimer’s Disease, hepatitis, diabetes, asthma, hypertension, and vaccines
- On average, each ACRO member works with more than 500 research sponsors and approximately 27,000 research sites annually
- ACRO members delivered more than 100 million central laboratory test results and managed more than 1 million square feet of lab space in 13 countries
- The top US states for CRO employment are North Carolina, Pennsylvania, Massachusetts, New Jersey, Texas and California; the top European locations for CRO employment are the United Kingdom, Germany, France and Spain
Throughout the next month, ACRO will be unveiling a series of case studies that highlight CRO innovation, as well as a video series focusing several of these topics.
Read the full release here.
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
